|Videos|July 12, 2018
Case Study: Recurrent Synovial Sarcoma
Advertisement
Episodes in this series
Transcript:
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The EMA validated the marketing authorization application for varegacestat in adults with desmoid tumors.
Risvutatug rezetecan delayed progression vs gemcitabine and docetaxel in patients with osteosarcoma after 2 or more prior systemic therapies.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC
2
BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC
3
Dr Cai on the Rationale for Evaluating Rocbrutinib Plus R-CHOP in Non-GCB DLBCL and MCL
4
Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
5